(VIANEWS) – Genmab (GMAB), Argan (AGX), Merchants Bancorp (MBIN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Genmab (GMAB)
42.2% sales growth and 14.87% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.95.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 30.36. Meaning, the purchaser of the share is investing $30.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.87%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Genmab’s EBITDA is 7.3.
Yearly Top and Bottom Value
Genmab’s stock is valued at $28.84 at 10:22 EST, way under its 52-week high of $42.99 and above its 52-week low of $27.74.
Sales Growth
Genmab’s sales growth is negative 4.5% for the ongoing quarter and 42.2% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 3200% and 5440%, respectively.
Previous days news about Genmab(GMAB)
- Genmab a/s sponsored ADR (gmab) May find a bottom soon, here's why you should buy the stock now. According to Zacks on Friday, 19 January, "The price trend for Genmab A/S Sponsored ADR (GMAB Quick QuoteGMAB – Free Report) has been bearish lately and the stock has lost 9.9% over the past week. ", "So, for the shares of Genmab A/S Sponsored ADR, a Zacks Rank of 2 is a more conclusive fundamental indication of a potential turnaround."
2. Argan (AGX)
23.7% sales growth and 12.78% return on equity
Argan, Inc., through its subsidiaries, provides engineering, procurement, construction, commissioning, operations management, maintenance, project development, technical, and consulting services to the power generation and renewable energy markets. The company operates through Power Industry Services, Industrial Fabrication and Field Services, and Telecommunications Infrastructure Services segments. The Power Industry Services segment offers engineering, procurement, and construction (EPC) contracting services to the owners of alternative energy facilities, such as biomass plants, wind farms, and solar fields; and design, construction, project management, start-up, and operation services for projects with approximately 15 gigawatts of power-generating capacity. This segment serves independent power project owners, public utilities, power plant equipment suppliers, and energy plant construction companies. The Industrial Fabrication and Field Services segment provides industrial field, and steel pipe and vessel fabrication services for forest products, power, energy, large fertilizer, EPC, mining, and petrochemical companies in southeast region of the United States. The Telecommunications Infrastructure Services segment offers trenchless directional boring and excavation for underground communication and power networks, as well as aerial cabling services; and installs buried cable, high and low voltage electric lines, and private area outdoor lighting systems. It also provides structuring, cabling, terminations, and connectivity that offers the physical transport for high speed data, voice, video, and security networks. This segment serves state and local government agencies, regional communications service providers, electric utilities, and other commercial customers, as well as federal government facilities comprising cleared facilities in the mid-Atlantic region of the United States. Argan, Inc. was founded in 1961 and is headquartered in Rockville, Maryland.
Earnings Per Share
As for profitability, Argan has a trailing twelve months EPS of $2.47.
PE Ratio
Argan has a trailing twelve months price to earnings ratio of 18.96. Meaning, the purchaser of the share is investing $18.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.78%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 38.9%, now sitting on 527.56M for the twelve trailing months.
3. Merchants Bancorp (MBIN)
16.4% sales growth and 17% return on equity
Merchants Bancorp operates as the diversified bank holding company in the United States. It operates through Multi-family Mortgage Banking, Mortgage Warehousing, and Banking segments. The Multi-family Mortgage Banking segment engages in the mortgage banking, which originates and services government sponsored mortgages including bridge financing products to refinance, acquire, or reposition multi-family housing projects, and construction lending for multi-family and healthcare facilities; offers customized loan products for need-based skilled nursing facilities, independent living, assisted living, and memory care; and tax credit equity syndicator. Its Mortgage Warehousing segment funds agency eligible residential loans including origination, purchase, and sale in the secondary market, as well as commercial loans to non-depository financial institutions. The Banking segment offers a range of financial products and services to consumers and businesses, which includes retail banking, commercial lending, agricultural lending, retail and correspondent residential mortgage banking, and small business administration lending. Merchants Bancorp was founded in 1990 and is headquartered in Carmel, Indiana.
Earnings Per Share
As for profitability, Merchants Bancorp has a trailing twelve months EPS of $5.17.
PE Ratio
Merchants Bancorp has a trailing twelve months price to earnings ratio of 8. Meaning, the purchaser of the share is investing $8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 28.6% and 27.1%, respectively.
Yearly Top and Bottom Value
Merchants Bancorp’s stock is valued at $41.37 at 10:22 EST, below its 52-week high of $43.89 and way higher than its 52-week low of $21.50.
Moving Average
Merchants Bancorp’s value is way higher than its 50-day moving average of $37.55 and way above its 200-day moving average of $29.67.
4. Baidu (BIDU)
6.1% sales growth and 9.65% return on equity
Baidu, Inc. offers internet search services in China. It operates through Baidu Core and iQIYI segments. The company offers Baidu App to access search, feed, and other services using mobile devices; Baidu Search to access its search and other services; Baidu Feed that provides users with personalized timeline based on their demographics and interests; Baidu Health that helps users to find the doctor and hospital for healthcare needs; and Haokan, a short video app. It also provides Baidu Knows, an online community where users can ask questions to other users; Baidu Wiki; Baidu Experience; Baidu Post; Baidu Wenku; Baidu Maps, a voice-enabled mobile app that provides travel-related services; Baidu Drive; Baijiahao; and DuerOS, a smart assistant platform. In addition, it offers online marketing services, which include pay for performance, an auction-based services that allow customers to bid for priority placement of paid sponsored links and reach users who search for information related to their products or services; other marketing services that include display-based marketing services and other online marketing services based on performance criteria other than cost per click; mobile ecosystem, a portfolio of apps, including Baidu App, Haokan, and Baidu Post; various cloud services and solutions, such as platform as a service, software as a service, and infrastructure as a service; self-driving services, including maps, automated valet parking, navigation pilot, electric vehicles, and robotaxi fleets, as well as Xiaodu smart devices. Further, the company provides iQIYI, an online entertainment service, including original and licensed content; other video content and membership; and online advertising services. Baidu, Inc. has strategic partnership with Zhejiang Geely Holding Group. The company was formerly known as Baidu.com, Inc. Baidu, Inc. was incorporated in 2000 and is headquartered in Beijing, China.
Earnings Per Share
As for profitability, Baidu has a trailing twelve months EPS of $6.
PE Ratio
Baidu has a trailing twelve months price to earnings ratio of 16.92. Meaning, the purchaser of the share is investing $16.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.65%.
Volume
Today’s last reported volume for Baidu is 1663430 which is 41.64% below its average volume of 2850760.
Yearly Top and Bottom Value
Baidu’s stock is valued at $101.51 at 10:22 EST, below its 52-week low of $103.32.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.9%, now sitting on 132.72B for the twelve trailing months.
Previous days news about Baidu(BIDU)
- According to Zacks on Wednesday, 17 January, "Alphabet, Baidu and Akamai are some of the larger players while Dropbox, Etsy, Shopify, Uber, Lyft and Trivago are some of the emerging players."
- According to Zacks on Thursday, 18 January, "Alphabet, Baidu and Akamai are some of the larger players while Dropbox, Etsy, Shopify, Uber, Lyft and Trivago are some of the emerging players."
- Baidu inc. (bidu) rises higher than market: key facts. According to Zacks on Thursday, 18 January, "The investment community will be closely monitoring the performance of Baidu Inc. in its forthcoming earnings report. ", "It is also important to note the recent changes to analyst estimates for Baidu Inc. Recent revisions tend to reflect the latest near-term business trends. "
